floblu14
3 days ago
Foley Hoag Recognized as 2024 Law360 "Regional Powerhouse" in Massachusetts
September 19, 2024
Law360 again recognized Foley Hoag LLP as a “Regional Powerhouse” in Massachusetts. The law firms on Law360’s list of 2024 Regional Powerhouses are driving some of the biggest deals and most high-profile courtroom battles, delivering top-tier regional expertise for clients and making a lasting impact on the law at the state and local level.
The Regional Powerhouses Series honors leading law firms in various states based on their exceptional achievements. In Massachusetts, Law360 recognized only three firms, including Foley Hoag. Law360 noted, “With some of the state's household-name clients under its belt and a former Massachusetts attorney general on its roster, Foley Hoag LLP is one of the state's premier law firms in a number of growing sectors.”
The recognition reflects the complex legal work performed for clients by Foley Hoag across cutting-edge industries, including life sciences, technology, energy and cannabis, and the results achieved. Law360 specifically highlighted the firm’s representations of:
Enanta Pharmaceuticals in a patent litigation involving Pfizer's antiviral COVID treatment Paxlovid.
https://www.foleyhoag.com/news-and-insights/news/2024/september/foley-hoag-recognized-as-2024-law360-regional-powerhouse-in-massachusetts/
The "proof is in the pudding". Let's hope Hoag representation will be positive for ENTA.
Again, representing the Plaintiff, Enanta:
https://foleyhoag.com/people/fiacco-barbara/
vinmantoo
1 week ago
The cash is real, royalty sale is real and then the pipeline result so far looks real
You would think this is at least a mid 20 dollars stock
Yes, ENTA is in a better financial position but there is uncertainty. Their Covid drug, EDP-235 sits on the shelf and EDP-514, their HepB drug is also sitting on the shelf. For EDP-235, ENTA won't move forward without a partner.
For EDP-514, ENTA needs to find another drug to combine with a nucleoside, either in house or for a more rapid developmental pathway, partner with another company which has a promising HepB drug.
For RSV, a strong result in the challenge trial of EDP-323 would provide a backup for EDP-938 in case the latter fails in the Peds and or high risk adult group. There might also be a combo trial of 323 and 938 if the latter doesn't show stellar results.
ENTA has yet to select a candidate for their Kit inhibitor program.
The lawsuit against PFE remains a wildcard.
ENTA is a decent chunk of my biotech portfolio and my position is down ~40%, by far the worst of my holdings. The revenue stream from HepC stabilizes ENTA but I am under no illusions. ENTA has signifcant risk but the upside can be large. Good luck to us both!
go seek
1 week ago
And read this study… EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge in the NEJM.
One needs to compare apples to apples.
Both studies are Challenge Studies, where healthy individuals are inoculated with the virus and symptoms, viral loads and safety are analyzed before and after dosage with the virus inhibitor. The primary end point was the area under the curve (AUC) for the RSV viral load, as measured by reverse-transcriptase–quantitative polymerase-chain-reaction assay. The key secondary end point was the AUC for the total symptom score. Low AUC is better than high AUC.